Metabolic <i>N</i>-Dealkylation and <i>N</i>-Oxidation as Elucidators of the Role of Alkylamino Moieties in Drugs Acting at Various Receptors

• Main Author: Babiker M. EH-Haj
• Format: Article
• Language: English
• Published: MDPI AG 2021-03-01
• Series: Molecules
• Subjects: <i>N</i>-alkylamino moieties; metabolic <i>N</i>-dealkylation; metabolic <i>N</i>-oxidation; pharmacologic activity; physicochemical properties; <i>N</i>-desalkylamino metabolite drugs
• Online Access: https://www.mdpi.com/1420-3049/26/7/1917

Metabolic<b> </b>reactions that occur at alkylamino moieties may provide insight into the roles of these moieties when they are parts of drug molecules that act at different receptors. <i>N</i>-dealkylation of <i>N</i>,<i>N</i>-dialkylamino moieties has been associated with retaining, attenuation or loss of pharmacologic activities of metabolites compared to their parent drugs. Further, <i>N</i>-dealkylation has resulted in clinically used drugs, activation of prodrugs, change of receptor selectivity, and providing potential for developing fully-fledged drugs. While both secondary and tertiary alkylamino moieties (open chain aliphatic or heterocyclic) are metabolized by CYP450 isozymes oxidative <i>N</i>-dealkylation, only tertiary alkylamino moieties are subject to metabolic <i>N</i>-oxidation by Flavin-containing monooxygenase (FMO) to give <i>N</i>-oxide products. In this review, two aspects will be examined after surveying the metabolism of representative alkylamino-moieties-containing drugs that act at various receptors (i) the pharmacologic activities and relevant physicochemical properties (basicity and polarity) of the metabolites with respect to their parent drugs and (ii) the role of alkylamino moieties on the molecular docking of drugs in receptors. Such information is illuminative in structure-based drug design considering that fully-fledged metabolite drugs and metabolite prodrugs have been, respectively, developed from <i>N</i>-desalkyl and <i>N</i>-oxide metabolites.